

MarketVue®

# Arrhythmogenic Cardiomyopathy

October 2023



# MarketVue®: Arrhythmogenic Cardiomyopathy

UNDERSTAND THE ARRHYTHMOGENIC CARDIOMYOPATHY MARKET

**MarketVue** market landscape reports combine primary (KOL interviews) and secondary market research to empower strategic decision-making and provide a complete view of the market.

Every **MarketVue** includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

**Methodology:** Research is supported by 13 qualitative interviews with key opinion leaders and secondary research. Qualitative interview participants included 3 U.S. adult cardiac electrophysiologists, 4 U.S. cardiologists, 2 U.S. pediatric electrophysiologists, 3 IT cardiologists, and 1 FR cardiologist.

**Geographies covered:** United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

## TOPICS COVERED

**EPIDEMIOLOGY:** Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments

**CURRENT TREATMENT:** Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment

**UNMET NEEDS:** Identify opportunities to address treatment or disease management gaps

**PIPELINE ANALYSIS:** Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs

**VALUE AND ACCESS:** Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

## Why MarketVue?

- **PMR-Driven** – Insights informed by qualitative interviews and/or quantitative surveys
- **Senior Team** – Experienced team members (10+ years in pharma market research) lead the research
- **Strategic** – Delivered in a concise and strategic report template vetted by pharmaceutical industry professionals
- **Fresh** – New reports or report refreshes delivered in as little as 15 business days



# MarketVue®: Arrhythmogenic Cardiomyopathy

UNDERSTAND THE ARRHYTHMOGENIC CARDIOMYOPATHY MARKET

## COMPANIES MENTIONED

- Rocket Pharmaceuticals
- Lexeo Therapeutics
- Tenaya Therapeutics
- StrideBio / Ginko Bioworks
- Ginkgo
- BioMarin Pharmaceuticals

## DRUGS MENTIONED

- Beta blockers
- Sotalol (Betapace, Sorine)
- ACE inhibitors
- RP-A601
- TN-401
- STRX-330
- LX2020
- BMN365
- Spironolactone
- Flecainide (Tambocor)

# MarketVue®: Arrhythmogenic Cardiomyopathy

## Table of Contents

<b>1. DISEASE OVERVIEW</b>	<b>5</b>
A life-threatening, progressive inherited genetic condition impacting cardiac function	5
Table 1.1. Most common ACM mutations	5
Figure 1.1. Pathogenesis of ACM	5
<b>2. EPIDEMIOLOGY &amp; PATIENT POPULATIONS</b>	<b>6 - 7</b>
Prevalence of ACM	6
Table 2.1. ACM diagnosed prevalence in the United States, 2023	6
Figure 2.1. Prevalence estimates of ACM in the medical literature from 1994 - 2022	6
Disease definition	7
Figure 2.2. Diagnosed prevalent cases of PKP2+ ACM by region	7
Table 2.2. Diagnosed prevalent ACM cases in the US and EU5	7
Table 2.3 Average prevalence of ACM mutation type	7
<b>3. DIAGNOSIS AND CURRENT TREATMENT</b>	<b>8 - 13</b>
Diagnosis overview	8
Figure 3.1. Diagnostic pathway for ARVC patients	8
Figure 3.2. Physician-reported average estimate of ACM patients that receive a diagnosis	8
ACM genetic testing dynamics	9
Figure 3.3. KOL estimate of their ACM patients who are PKP2+ with genetic testing	9
Figure 3.4. Physician-reported barriers to genetic testing	9
ACM treatment involves pharmacological and device interventions	10
Figure 3.5. Treatment algorithm for management of ACM	10
Figure 3.6. ACM treatment goals	10
ACM treatment dynamics	11
Figure 3.7. Current Treatment Patient Share	11
Table 3.1. Current ACM treatment outcomes	11
Table 3.2. Upsides and downsides of current interventions used for ACM	11
Key treatment dynamics that shape disease management and novel therapy use in ACM	12
Table 3.3. Must-know ACM market dynamics	12
Key treatment dynamics that shape disease management and drug use in ACM	13
Figure 3.8. Important dynamics of ACM market evolution	13

# MarketVue®: Arrhythmogenic Cardiomyopathy

## Table of Contents

<b>4. UNMET NEED</b>	<b>14 - 16</b>
Overview	14
Figure 4.1. Top unmet needs in ACM	14
Figure 4.2. Physician-reported perspectives on ACM treatment	14
ACM disease burden and unmet needs	15
Figure 4.3. Physician-reported disease burden for ACM patients and families	15
Table 4.1. Most important attributes for new ACM treatment	15
Physician perspectives on unmet needs in ACM	16
<b>5. PIPELINE ANALYSIS</b>	<b>17 - 22</b>
Overview	17
Table 5.1 Summary of the RP-A601 gene therapy trial	17
ACM therapies in early pipeline follow similar framework	18
Table 5.2. Comparison of preclinical ACM gene therapies	18
Investigator-sponsored drug-based approaches to ACM	19
Figure 5.1. Estimated proportion of population with positive AAV titers	19
Table 5.3. Investigator-sponsored ACM trials	19
Gene therapy in ACM	20
Table 5.4. Physician-reported perspectives on ACM treatment and gene therapies	20
Table 5.5. Attributes that will drive uptake for emerging ACM therapies	20
Future considerations for gene therapy	21
Table 5.6. Opportunities and threats for emerging AAV-based ACM gene therapies	21
Physician perspectives on ACM gene therapies	22
<b>6. VALUE &amp; ACCESS</b>	<b>23 - 24</b>
Overview	23
Table 6.1. Comparison of gene therapy pricing, U.S.	23
Figure 6.1. Key reimbursement and access considerations for emerging therapies in ACM	23
Key insights from the ACM market	24
Table 6.2. Innovative payer coverage gene therapy insights	24

# MarketVue®: Arrhythmogenic Cardiomyopathy

## Table of Contents

### 7. METHODOLOGY

25 - 26

Primary market research approach	25
Epidemiology methodology	25
Table 7.1. ACM prevalence and population size references	25
PKP2 Mutation Rate Methodology	26
Table 7.2. Mutation rate references	26
Table 7.3. Pharmaceutical company ACM and PKP2 prevalence estimates	26

# Meet the REACH Team



**DANIELLE DRAYTON, PhD.**, Dr. Drayton is CEO and Founder of REACH Market Research. She is a seasoned business leader and pharmaceutical market researcher. Prior to founding REACH, Dr. Drayton led the Biopharma Market Assessment business at Decision Resources Group (DRG) comprised of market research, RWD analytics, and consulting business lines. In her 14 years at DRG, she worked with 48 of the top 50 pharmaceutical companies and countless biotech companies that involved exhaustive evaluation of unmet need, target product profiles, commercial potential and new product adoption, and company competitiveness. She also has extensive experience conducting product and market opportunity assessments, portfolio analysis, product and therapeutic area strategy, product valuation and sales forecasting, and pre-launch planning. Dr. Drayton completed a postdoctoral fellowship at the Harvard Medical School, received a Ph.D. in Immunobiology from Yale University, and earned a B.S. in Microbiology and Immunology from the University of Miami (Florida).



**MELISSA CURRAN** is the Director of Product Management at REACH. Melissa has over 10 years of life sciences market research and consulting experience spanning from bespoke strategy consulting to syndicated market research product development and management. Prior to joining REACH, she worked at Decision Resources Group (DRG) for 7 years assisting pharmaceutical and biotechnology commercial teams across the product lifecycle to inform strategic decision making. Melissa is particularly passionate about new product planning and portfolio management, especially in the rare disease space where data can be scarce, and decision-making can be challenging. Specific types of strategic assessments Melissa specializes in include market landscape assessments, commercial opportunity assessment, patient journey mapping, product positioning and TPP optimization, portfolio prioritization, and competitive intelligence. She also has extensive experience working across various market research methodologies including qualitative interviews, quantitative surveys, patient chart audits, real world claims and EHR data, conjoint analysis and secondary research. Melissa received her bachelor's degree in Biology and minor in Business from Providence College.



**MICHAEL HUGHES, MSc, Ph.D.**, Dr. Hughes is the Director of Research at REACH. He has worked in academia, regulatory affairs (NICE) and in RWE and epidemiology consultancies, leading the global epidemiology team at Clarivate (previously Decision Resources Group) for many years. Over that period, he has built numerous new approaches to epidemiological forecasting and imputation, which now form industry best-practice. He has built syndicated and custom epidemiological models and forecasts for many blockbuster drugs across many therapeutic areas, often using a hybrid approach sourcing data from multiple types of dataset and primary market research. He has recently worked on projects in prostate cancer, amyloidosis, anaphylaxis and multi-drug resistant UTIs, among others. He has supported the needs of both big pharma, including Novartis, GSK and Johnson and Johnson, as well as smaller companies and biotechs.

# Meet the REACH Team



**TYLER JAKAB, MPH** is an analyst at REACH Market Research. He is responsible for conducting both primary and secondary market research regarding rare disease therapies to be integrated into market research reports for life science clients. Tyler is a recent graduate of Boston University School of Public Health where he obtained an MPH in Epidemiology of Biostatistics. Prior to joining REACH, he held roles in which he was responsible for health policy analysis, tobacco control research, and health communication. He has extensive experience in data analysis, as well as manuscript and report writing. Tyler also earned a BS in Psychology and Anthropology from the University of North Carolina at Chapel Hill.



**BAYLEY KOOPMAN** is a Research Associate at REACH Market Research. At REACH, Bayley supports both primary and secondary market research through literature reviews and working with qualitative data. He recently graduated from Tufts University with a B.S. in Biology where he studied the interdisciplinary OneHealth approach for public health and the environment. During this time, Bayley founded an early-stage consumer product startup, which became a finalist team in two consecutive Tufts University Entrepreneurship Pitch Competitions. Prior to joining REACH, Bayley also held roles in regulatory affairs in the rare-disease pharmaceutical industry and veterinary practice.



**BRIANA MULLINS** is a current PhD student At NYU School of Medicine studying the immunological progression of disease in psoriatic arthritis. She currently does both laboratory research and computational biology. Previously she earned her undergraduate degree in Biochemistry at New York University (NYU) and worked in the Blaser Lab studying the human microbiome. She also received an MSc. in Population Health at the University College London (UCL) and conducted antibiotic prescription research using the UK THIN Database. Before starting her PhD Briana worked at Decision Resources Group as an Associate Epidemiologist.